Gilead Sciences, Inc. received approval from the U.S. FDA for its antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. The FDA previously authorized Veklury for emergency use to treat COVID-19. Veklury is now the first and only approved COVID-19 treatment in the U.S. The drug is now widely available in hospitals across the country, following...